% | $
Quotes you view appear here for quick access.

Amylin Pharmaceuticals, Inc. Message Board

  • terry_amln terry_amln May 1, 2011 10:00 AM Flag

    Diabetes close-up issue (Kelly Close)

    "While we were surprised that Amylin/Lilly/Alkermes' Bydureon did not meet efficacy expectations against Victoza in DURATION-6, and while we wait for further word on this data, its once-weekly dosing still represents a major advance for patients, as does the vastly improved side effect profile. When it's in its next-gen pen form, we think the interest in GLP-1 will increase further quite dramatically. Meanwhile, Novo Nordisk's Degludec will likely carry less risk of hypoglycemia, and the phase 3 program for co-formulation with Victoza - the first basal insulin/GLP-1 combination to make it this far - is set to begin in May.


    Kelly L. Close